Skip to main content
Equibles
FULC logo

FULC · Fulcrum Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track FULC — free

Use FULC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FULC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.69 +0.01 (+0.27%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$285.35M
Shares
76.30M
Volume · Oct 2 1.54M Avg daily vol (3M) 1.59M

Fulcrum Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Fulcrum Therapeutics, Inc. (FULC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲19.7% $5.06M −$23.48M '21 Q4 22-03-03 ▼45.9% $2.59M −$25.93M '22 Q1 22-05-09 ▼57% $1.88M −$34.07M '22 Q2 22-08-11 ▼76% $1.18M −$23.74M '22 Q3 22-11-08 ▼88.6% $295,000 −$24.78M '23 Q1 23-05-15 ▼53.2% $880,000 −$23.78M '23 Q2 23-08-03 ▼35.8% $759,000 −$24.02M '23 Q3 23-11-07 ▲27.2% $871,000 −$24.76M '23 Q4 24-02-27 ▼100% $ −$26.87M '24 Q1 24-05-13 ▲8990.9% $80.00M $55.41M '24 Q2 24-07-31 ▼100% $ −$21.70M '24 Q3 24-11-13 ▼100% $ −$16.57M '24 Q4 25-02-25 LATEST ▼100% $ −$17.30M '25 Q2 25-07-29
Earnings call
FY26 · Q1
2026-04-27
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
Confident tone Next trial design and FDA end-of-Phase meeting Global development and EMA engagement Combination strategy with hydroxyurea and other mechanisms
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
Confident tone PIONEER 20mg cohort efficacy VOC reduction trend Best-in-class positioning
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-07-29
Fulcrum Therapeutics, Inc. (FULC) Q2 2025 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.28
▼ 132.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript
Confident tone Pociredir PIONEER Phase 1b trial Earlier-stage pipeline (inherited anemias) Patient enrollment and adherence
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
Positive tone Fetal hemoglobin mechanism and unmet need in sickle cell Pociredir PIONEER trial progress FDA interactions and regulatory pathway
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Balanced tone Pociredir (PIONEER trial) for sickle cell disease Phase 1 healthy volunteer trials and FDA interactions Clinical trial site activation and enrollment progress
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call Transcript
Positive tone Phase 3 REACH trial Pociredir profile Sanofi collaboration
Revenue
$80.00M
▲ 8990.9% YoY
Diluted EPS
$0.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
Confident tone Losmapimod REACH Phase III trial in FSHD U.S. commercial launch readiness for 2026 FDA and EMA regulatory interactions and endpoint acceptance
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript
Positive tone Losmapimod REACH Phase 3 in FSHD Pociredir for sickle cell disease Payer access, pricing, and genetic testing
Revenue
$871,000*
▲ 27.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Fulcrum Therapeutics, Inc. (FULC) Q3 2023 Earnings Call Transcript
Revenue
$759,000
▼ 35.8% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Call Transcript
Revenue
$880,000
▼ 53.2% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Fulcrum Therapeutics, Inc. (FULC) Q1 2023 Earnings Call Transcript
Revenue
$295,000
▼ 88.6% YoY
Diluted EPS
$-0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-08
Fulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call Transcript
Revenue
$1.18M
▼ 76% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Fulcrum Therapeutics, Inc. (FULC) Q2 2022 Earnings Call Transcript
Revenue
$1.88M
▼ 57% YoY
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Fulcrum Therapeutics, Inc. (FULC) Q1 2022 Earnings Call Transcript
Revenue
$2.59M
▼ 45.9% YoY
Diluted EPS
$-0.64
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Fulcrum Therapeutics, Inc. (FULC) Q4 2021 Earnings Call Transcript
Revenue
$5.06M*
▲ 19.7% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Fulcrum Therapeutics, Inc. (FULC) Q3 2021 Earnings Call Transcript
Revenue
$4.93M
▲ 167% YoY
Diluted EPS
$-0.57
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Fulcrum Therapeutics, Inc. (FULC) Q2 2021 Earnings Call Transcript
Revenue
$4.38M
▲ 119% YoY
Diluted EPS
$-0.60
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Fulcrum Therapeutics, Inc. (FULC) Q1 2021 Earnings Call Transcript
Revenue
$4.79M
▲ 538.5% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q3
2020-11-10
Fulcrum Therapeutics, Inc. (FULC) Q3 2020 Earnings Call Transcript
Revenue
$1.85M
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Fulcrum Therapeutics, Inc. (FULC) Q2 2020 Earnings Call Transcript
Revenue
$2.00M
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript
Revenue
$750,000
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–23 of 23 webcasts
Key facts CIK 1680581 CUSIP 359616109 13F (30d) 2 filings 2 filers Visit website Investor relations